Updated: Maze reveals positive first look at PhI Pompe disease candidate

Nicole DeFeudis

Editor

The scientists at Maze Therapeutics call themselves “genetic navigators,” and on Thursday, they mapped out some positive Phase I results from their most advanced program …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Updated: Maze reveals positive first look at PhI Pompe disease candidate

Nicole DeFeudis

Editor

Sign up to read this article for free.

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

FDA says Ozempic, Wegovy shortage is over

How AI can address ongoing challenges in the life sciences industry

Up­dat­ed: Maze re­veals pos­i­tive first look at PhI Pompe dis­ease can­di­date

Nicole DeFeudis

Editor

Sign up to read this article for free.

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

FDA says Ozem­pic, We­govy short­age is over

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

Updated: Maze reveals positive first look at PhI Pompe disease candidate

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

FDA says Ozempic, Wegovy shortage is over

How AI can address ongoing challenges in the life sciences industry